Physicians

For information about YM BioSciences' products and ongoing clinical studies, please click the appropriate link below.

Nimotuzumab

  • Indication: Cancer
  • Monoclonal antibody
  • Ongoing Phase I, Phase II and Phase III clinical studies for lung cancer, pediatric and adult glioma, esophageal cancer, pancreatic cancer, prostate cancer, gastric cancer, cervical cancer, hepatic carcinoma and breast cancer
  • Approved for sale in certain countries 


CYT387

  • Indication: Hematological disorders known as myeloproliferative neoplasms (MPNs), also known as myeloproliferative disorders
  • JAK 1/2 small molecule inhibitor
  • Ongoing Phase I/II clinical study


CYT997


AeroLEF®

  • Indication: Moderate to severe acute pain
  • Inhaled-delivery composition of free and liposome-encapsulated fentanyl
  • Phase II clinical studies completed
  • Phase III clinical studies planned